

Preliminary Scientific Program

as at 7 August 2019, subject to change

Monday 25 November 2019

08:30 – 17:00	Beginner Population Approach workshop (Pharmacometrics)	Intermediate Population Approach workshop (Pharmacometrics)
17:00 – 17:45	PAGANZ AGM	
18:00 – 19:30	ASCEPT Board meeting	

Tuesday 26 November 2019

08:00 – 18:00	Registration desk open		
08:30 – 12:30	Careers workshop (09:00 – 12:30)	Pharmacogenomics workshop (10:30 – 12:30)	Clinical Pharmacology workshop (08:30 – 12:30 including AGM)
		Chair: Prof Andrew Somogyi	
		10:30 – 10:35 Welcome & introduction Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG 10:35 – 11:15 Application of new tools to understand the genetics of adverse drug reactions Prof Martin Kennedy, Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand 11:15 – 11:40 Precision medicine for type 2 diabetes Assoc Prof Rinki Murphy, University of Auckland, Auckland, New Zealand 11:40 – 12:05 ECR/student talks 12:05 – 12:30 Pharmacogenomics SIG AGM	
12:30 – 13:30	Break (delegates to make their own arrangements for lunch at their expense)		
13:30 – 16:30		Education Forum	Neuropharmacology/Drug Discovery workshop
		Showcase of teaching initiatives Round table discussion of issues in pharmacology education Education Forum AGM	
16:30 – 17:00	Comfort break		
17:00 – 18:00	Conference opening and keynote address		
	Prof Donald Mager, University of Buffalo, USA		
18:00 – 19:30	Welcome reception Reds Bar, Rydges Lakeland Resort		

Wednesday 27 November 2019

07:30 – 18:00	Registration desk open		
08:00 – 09:00	ASCEPT Rand Medal lecture Prof Patrick Sexton, Monash Institute of Pharmaceutical Sciences, Monash University		
09:00 – 10:30	Oral presentations 1:	Oral presentations 2:	Oral presentations 3:
10:30 – 11:10	Morning tea with exhibitors Poster presentations		
11:15 – 13:15	Symposium 1: Novel pharmacotherapies for cardiopulmonary and respiratory diseases Chairs: Assoc Prof Barbara Kemp-Harper, Monash University and Prof Ross Vlahos, RMIT University, Australia	Symposium 2: Innovative strategies to optimise medicine use in the older population to improve health outcomes Chairs: Prof Sepehr Shakib, University of Adelaide, Australia and Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	Symposium 3: Molecular control of G protein-coupled receptor efficacy Chairs: Prof Patrick Sexton, Monash University, Australia and Prof Debbie Hay, University of Auckland, New Zealand
	The translational potential of targeting natriuretic peptide-cGMP pathways in the treatment of pulmonary arterial hypertension Prof Adrian Hobbs, William Harvey Research Institute, UK	Complexity and clinical implications of multiple chronic conditions and polypharmacy in the older population Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	Proximal study of biased agonism at G protein-coupled receptors Dr Peishen (Elva) Zhao, Monash University, Australia
11:45 – 12:15	Pharmacological therapies to target reactivity and remodelling in cardiopulmonary disease Dr Jane Bourke, Monash University, Australia	A multi-country network to improve medicine use in people with Dementia: The NeuroGEN Collaboration Dr Jenni Ilomaki, Monash University, Australia	Unravelling the molecular basis of biased agonism using cryo-EM Assoc Prof Denise Wootten, Monash University, Australia
12:15 – 12:45	Novel therapeutic strategies for the treatment of chronic obstructive pulmonary disease Assoc Prof Chrishan Samuel, Monash University, Australia	Methodological challenges and innovative solutions: Understanding the complexity of pharmacoepidemiological studies in the older population Prof Olaf Klungel, University of Utrecht, The Netherlands	The molecular basis of transmembrane signaling Dr Andrew Kruse, Harvard Medical School, USA
12:45 – 13:15	Targeting pathological inflammation in asthma with G-CSFR antagonists Prof Steven Bozinovski, RMIT University, Australia	Clinical decision support tools for prescribing in the older population: From qualitative dashboards to quantitative modelling and simulation to enable precision dosing Dr Tom Polasek, Certara, Australia	Dr Arun Shukla, Indian Institute of Technology, India
13:15 – 14:10	Lunch with exhibitors Poster presentations		
14:15 – 15:45	Oral presentations 4:	Oral presentations 5:	Oral presentations 6:
15:45 – 16:10	Afternoon tea with exhibitors		
16:15 – 18:15	Certara New Investigator Award Discovery of novel peptide ligands for orphan G protein-coupled receptors Dr Simon Foster, Monash University, Australia The roles of aerosolized polymyxins in the treatment of lung infections: A step towards dose optimisation Dr Yu-Wei (Wayne) Lin, Monash University, Australia Translational toxicovigilance: Preventing drug related harms through legislation and policy Dr Rose Cairns, The University of Sydney, Australia Gain from pain: Using venomous animals to explore new nociceptive pathways Dr Samuel Robinson, The University of Queensland, Australia		



Thursday 28 November 2019

07:30 – 17:00	Registration desk open		
08:00 – 08:30	Gillian Shenfield Early Educator Award		
08:30 – 09:00	Early Achievement Award for Women		
09:00 – 10:30	Oral presentations 7:	Oral presentations 8:	Oral presentations 9:
10:30 – 11:10	Morning tea with exhibitors Poster presentations		
11:15 – 13:15	Symposium 4: SGLT2 inhibitors: How good are they really?	Symposium 5: Precision medicine in oncology: Beyond diagnosis	Symposium 6: Drug dosing in children – how to do it better!
	Chairs: Dr Jenni Ilomaki, Monash University, Australia and Assoc Prof Matt Doogue, University of Otago, New Zealand	Chairs: Prof Andrew Somogyi, University of Adelaide, Australia and Dr Cornelia Landersdorfer, Monash University, Australia	Chairs: Assoc Prof Noel Cranswick, Royal Children's Hospital, The University of Melbourne, Australia and Prof Jennifer Martin, The University of Newcastle, Australia
11:15 – 11:45	SGLT2 inhibitors: Evidence from RCTs Dr Ingrid Hopper, Monash University, Australia	Precision medicine in lung cancer treatment Prof Mark McKeage, University of Auckland, New Zealand	The principles of dosing, response variability, and dose individualisation challenges in children Dr Hesham Al-Sallami, University of Otago, New Zealand
11:45 – 12:15	SGLT2 inhibitors: Evidence from observational studies Prof Olaf Klungel, Utrecht University, The Netherlands	Establishment of a therapeutic drug monitoring programme for the treatment of childhood cancer patients in the UK Prof Gareth Veal, Newcastle University, UK	Dosing antibiotics: Method development in neonates Dr Amanda Gwee, Royal Children's Hospital, Australia
12:15 – 12:45	Emerging adverse drug reactions related to SGLT2 inhibitors Dr Jenni Ilomaki, Monash University, Australia	Comparison of target concentration intervention dosing tools for busulfan in children Dr Stefanie Hennig, The University of Queensland, Australia	Immunosuppression: Dosing and dose adjustment in children Dr David Metz, Royal Children's Hospital, Australia
12:45 – 13:15	SGLT2 inhibitors in clinical practice Assoc Prof Matt Doogue, University of Otago, New Zealand	Predicting severe life-threatening toxicity after fluoropyrimidine drugs Assoc Prof Nuala Helsby, University of Auckland, New Zealand	Biologics use in pregnant women and predicting the effects in their babies Dr Zheng Liu, University of Newcastle, Australia
13:15 – 14:10	Lunch with exhibitors Poster presentations		
14:15 – 15:45	Oral presentations 10:	Oral presentations 11:	Oral presentations 12:
15:45 – 16:10	Afternoon tea with exhibitors		
16:15 – 17:15	Japanese Pharmacological Society keynote address		
	Prof Yuji Ikegaya, The University of Tokyo, Japan		
17:15 – 18:15	ASCEPT AGM		
19:00 – 23:30	Meeting dinner Skyline Queenstown		

Friday 29 November 2019

08:00 – 12:30	Registration desk open		
08:30 – 09:30	British Pharmacological Society keynote address		
	Prof Amin Rostami-Hodjegan, University of Manchester, UK		
09:30 – 10:25	Morning tea with exhibitors Student poster finalists presentation		
10:30 – 12:30	Symposium 7: Gout: Moving towards centre stage	Symposium 8: Novel therapies for the treatment of stroke and neurological disorders	Symposium 9: Using simulation as a learning tool to develop work place readiness
	Chairs: Prof Richard Day and Dr Sophie Stocker, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	Chairs: Dr Michael De Silva, La Trobe University, Australia and Dr Lauren May, Monash University, Australia	Chairs: Dr Hesham Al-Sallami, University of Otago, New Zealand and Associate Prof Lynette Fernandes, University of Western Australia, Australia
10:30 – 11:00	Allopurinol at the coal face – can we really get to target with an old drug? Prof Lisa Stamp, University of Otago, New Zealand	Amnion epithelial cell therapy for stroke: Translation of experimental findings into a Phase I clinical trial Prof Chris Sobey, La Trobe University, Australia	Using patient simulation in the lecture theatre to introduce “real-life” scenarios Dr Clare Guilding, Newcastle University Medicine, Malaysia
11:00 – 11:30	Model-based dosing in patients with gout: The curious case of allopurinol Dr Daniel Wright, University of Otago, New Zealand	Tailoring metabotropic glutamate receptor 5 activity with biased allosteric modulators for neurodegenerative disorders Dr Karen Gregory, Monash University, Australia	Clinical Pharmacology Top Trumps for the gamification of student learning about medicines Assoc Prof Matt Doogue, Christchurch Hospital and University of Otago, New Zealand
11:30 – 12:00	Off indication medicines and novel strategies with potential to treat gout Prof Anthony Rodgers, UNSW Sydney, The George Institute for Global Health, UNSW Medicine. Australia	The delta-subunit selective GABAA receptor modulator, DS2, improves stroke recovery via an anti-inflammatory mechanism Dr Andrew Clarkson, University of Otago, New Zealand	Using simulations to develop proficiency in the application of pharmacokinetic concepts Dr Cornelia Landersdorfer and Dr David Shackelford, Monash University, Australia
12:00 – 12:30	What to do about adherence to urate lowering therapy Prof Richard Day, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	Molecular pharmacology of Cannabinoid Receptor 2, a promising immunomodulatory target Dr Natasha Grimsey, University of Auckland, New Zealand	Real-time simulation to help students become more confident and reflective practitioners Prof Steve Duffull, Otago University, New Zealand
12:30 – 13:00	Awards and meeting close		
13:00 – 13:30	Lunch		